ResMed Inc. (RMD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

ResMed CEO Mick Farrell highlighted strong, steady market growth, with U.S. device revenue growing at a 15% annualized rate from fiscal 2021 through fiscal 2026. Management characterized ResMed as a growth company and noted it recently issued formal guidance for the first time in response to investor demand. The conference discussion was set to address patient-volume growth, competition, GLP-1 therapies, margins and strategy.

Analysis

The investable signal is not the conference appearance but whether RMD’s newly introduced outlook formalizes a durable upgrade cycle in sleep-device demand. A credible volume-led outlook would support multiple expansion because RMD’s consumables and software mix creates operating leverage after the initial device placement; conversely, guidance reliant on pricing or channel replenishment would be lower quality and vulnerable to reversal. The key diligence item is the split between new patient starts, replacement demand, and reseller inventory, none of which is independently established by management commentary alone.

Competitive dynamics remain asymmetric. RMD is positioned to capture incremental share if sleep-lab and home-testing capacity remain constrained, since providers generally favor integrated device, mask, and monitoring workflows; this would pressure smaller respiratory-equipment vendors and make a recovery in PHG’s sleep franchise harder. The non-obvious offset is GLP-1 adoption: meaningful weight loss could reduce obstructive-sleep-apnea severity over 12-36 months, but expanded primary-care screening and better diagnosis may initially increase treatment penetration rather than reduce device starts. Near-term, GLP-1 risk is more likely a valuation debate than an earnings impairment unless RMD begins reporting weaker diagnosis, setup, or replenishment trends.

Consensus may overreact to optimistic management language given the limited new disclosure in a conference format. The catalyst path over the next 1-3 months is investor-day, channel-data, or earnings confirmation of volume and gross-margin progression; over 6-18 months, the relevant question is whether software/consumer-health adjacencies improve retention enough to offset GLP-1-driven reductions in treatment intensity. Thesis falsification would be a guide cut, declining mask resupply rates, evidence of distributor destocking, or a material acceleration in GLP-1-treated apnea patients reducing PAP initiation rates.

Key Decisions for Investors

• Maintain RMD as a watch-to-buy rather than chase conference-driven strength; initiate only after the next reported quarter confirms that device growth is patient-volume led and management reiterates or raises outlook. A post-results entry with a 8-10% downside stop is preferable to underwriting an unverified guidance narrative.
• Express relative share gains through long RMD / short PHG in equal dollar size over a 3-6 month horizon, but only if PHG remains exposed to sleep-respiratory execution risk. Exit if PHG demonstrates sustained sleep-device availability and share stabilization, or if RMD reports slowing new-patient setups.
• Monitor quarterly indicators: U.S. sleep-test volumes, RMD device revenue versus mask/accessory growth, and resupply adherence. A widening gap in favor of recurring masks/software would justify increasing RMD exposure because it improves earnings durability and supports a higher valuation multiple.
• Do not position around MS from this event; the conference hosting role has no identifiable earnings transmission mechanism.